Effect on Patient Reported Outcomes of VATS and SABR (LILAC)

计划入组 244 人 · 首次发布于 2016 年 8 月 30 日

Implementation Research on the LILAC Method to Educate Management of Elevated Lipoprotein(a).

计划入组 20,000 人 · 首次发布于 2025 年 9 月 17 日

The Lilac Device Trial - IMPACT: A Clinical Investigation on IMproving Peripheral Neuropathy Induced by Chemotherapy With Advanced Compression Technology - A Safety and Efficacy Study

计划入组 142 人 · 首次发布于 2025 年 8 月 26 日

Glycopyranosyl lipid adjuvant (Revelation Biosciences)

Gut-Restricted TGF-Beta Receptor 1 Kinase Inhibitor (Enveda Biosciences)

PIN1(Larkspur Biosciences)

AURA BIOSCIENCES

India

Assembly Biosciences

United States

EUROMI BIOSCIENCES

France

Lilac Biosciences and Soin Neuroscience Publish Clinical Review on RNA Biomarkers for Objective Neuropathic Pain Assessment

LILAC-TIMI 76 Trial Evaluates Factor XI Inhibitor for Atrial Fibrillation Patients

FDA Grants Orphan Drug Designation to Pilatus Biosciences' PLT012 for Liver and Bile Duct Cancer